Atossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023
22 juin 2023 16h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE, June 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
21 juin 2023 10h13 HE
|
Atossa Therapeutics, Inc.
SEATTLE, June 21, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLC
14 juin 2023 09h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE, June 14, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
12 juin 2023 09h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE, June 12, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
01 juin 2023 09h10 HE
|
Atossa Therapeutics, Inc.
SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
15 mai 2023 09h10 HE
|
Atossa Therapeutics, Inc.
Two Phase 2 trials investigating (Z)-endoxifen in neoadjuvant setting initiated and are enrolling patientsFull enrollment of Phase 2 KARISMA mammographic breast density study expected by end of...
Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
09 mai 2023 09h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Therapeutics to Participate in Tribe Public’s Webinar Event “Redefining Breast Cancer Prevention and Treatment”
27 avr. 2023 09h15 HE
|
Atossa Therapeutics, Inc.
Virtual webinar scheduled for Thursday, May 4 at 8:00 am pacific / 11:00 am easternMeet with Atossa’s Founder and CEO, Steven Quay, M.D., Ph.D.Event is open to the public – registration available at...
Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update
22 mars 2023 16h05 HE
|
Atossa Therapeutics, Inc.
SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial
21 mars 2023 09h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE and SAN FRANCISCO, March 21, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of...